feature photo

Publications

 

IMPAACT at AIDS 2018

AIDS 2018

See more on the AIDS website


Accepted Abstracts for HIV Pediatrics Workshop 2018

Protocol
Title
Authors
Presentation Type


P1074/ CIPHER


Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a CIPHER cohort collaboration global analysis


Patel K, Smith C, Collins IJ, Goodall R, Abrams E, Sohn A, Mohamed T, Van Dyke R, Rojo P, Wools-Kaloustian K, Pinto J, Edmonds A, Marete I, Paul M, Nuwaqaba-Biribonwoha H, Leroy V, Davies M-A, Vreeman R, CIPHER Cohort Collaboration Duration of Second-line Proj


Oral presentation


P1076


Alendronate improves bone mineral density in perinatally HIV-infected children and adolescents


Jacobson D, Lindsay J, Spiegel H, Hazra R, Siberry G, for the IMPAACT P1076 Study Team


Oral presentation


PROMISE 1077BF


Role of maternal viral load and CD4 count on perinatal HIV-1 transmission during breastfeeding in the PROMISE postpartum component


Flynn P, Taha T, Cababasay M, Butler K, Fowler MG, Mofenson L, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanshanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga B, Masenya M, Nyati M, Theron G, Mulenga H, Shapiro D, and the PROMISE Study Team


Oral presentation


PROMISE 1077BF


Intracellular concentrations of tenofovir diphosphate (TFV-DP) during pregnancy in the PROMISE study: Description and relationship with adverse pregnancy outcomes


Aizire J, Brooks KM, Mirochnick M, Flynn P, Cababasay M, Kiser JJ, Siberry G, Fenton T, Butler K, Fowler MG, and the PROMISE Study Team


Poster presentation


P1104s


Caregiver depression and child neuropsychological outcomes in an observational study carried out in four Sub-Saharan countries


Familiar I, Chernoff M, Ruiseñor-Escudero H, Laughton B, Joyce C, Fairlie L, Bwakura-Dangarembizi M, Kamthunzi P, Barlow L, Jean-Philippe P, Zimmer B, McCarthy K, Boivin M


Oral presentation


P1110


IMPAACT P1110: Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: Dose-finding study in infants born to mothers receiving raltegravir-containing ART


Clarke D, Acosta E, Chain A, Cababasay M, Wang J, Teppler H, Smith E, Hazra R, Popson S, Graham B, Calabrese K, Bryson Y, Spector S, Mirochnick M


Poster presentation,
12:45 – 14:00;

Poster discussion,
17:00 – 17:30

P1101


Phase I/II study of raltegravir-containing regimen in HIV and TB co-treated children aged 6-<12 years


Krogstad P, Samson P, Meyers T, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Hovind L, Sise T, Teppler H, Dittmer S, Fairlie L, Hesseling AC, Cotton MF


Poster presentation

Accepted Abstracts for AIDS 2018

Protocol
Title
Authors
Presentation Type


P1093


Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to < 6 years: Results from IMPAACT P1093


Ruel T, Acosta E, Singh R, Alvero C, Fenton T, George K, Popson S, Townley E, Hazra R, Brothers C, Vavro C, Buchanan A, Wiznia A, IMPAACT P1093 Team


Poster presentation, Hall 1,
12:30 – 14:30 (LBPEB023)

Tuesday, 24 July


P1104s


Caregiver depression and child neuropsychological outcomes in an observational study carried out in four Sub-Saharan countries


Familiar I, Chernoff M, Ruisenor-Escudero H, Laughton B, Joyce C, Fairlie L, Bwakura-Dangarembizi M, Kamthunzi P, Barlow L, Jean-Philippe P, Zimmer B, McCarthy K, Boivin M


Poster presentation, Hall 1,
12:30 – 14:30 (TUPEC222)

Wednesday, 25 July

P1026s


Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum


Momper JD, Best B, Wang J, Stek A, Shapiro DE, George K, Barr E, Rungruengthanakit K, Smith E, Chakhtoura N, Capparelli EV, Mirochnick M


Poster presentation, Hall 1,
12:30 – 14:30 (WEPEB118)

P1074/ CIPHER


Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a CIPHER cohort collaboration global analysis


Patel K, Smith C, Collins IJ, Goodall R, Abrams E, Sohn A, Mohamed T, Van Dyke R, Rojo P, Wools-Kaloustian K, Pinto J, Edmonds A, Marete I, Paul M, Nuwaqaba-Biribonwoha H, Leroy V, Davies M-A, Vreeman R, CIPHER Cohort Collaboration Duration of Second-line Proj


Oral abstract,
Hall 10, 14:30 – 16:00
(WEAB0203)


PROMISE

Developmental and cognitive effects of type of antepartum and postpartum ARV exposure for Ugandan and Malawian IMPAACT PROMISE HIV-exposed versus unexposed children at age 12, 24 and 48 months


Boivin M, Maliwichi-Senganimalunje L, Wambuzi Ogwang L, Kawalazira R, Sikorskii A, Familiar-Lopez I, Kuteesa A, Nyakato M, Mutebe A, Makitende M, Mallewa M, Ruisenor-Escudero H, Aizire J, Taha T, Fowler MG


Oral presentation, Hall 10,
14:30 – 14:45 (WEAB0201)

Thursday, 26 July

P1093


Emergence of resistance in HIV-1 integrase (IN) following dolutegravir (DTG) treatment in 6 to 18 year old participants enrolled in the P1093 study


Vavro C, Ruel T, Wiznia A, Alvero C, Popson S, Fenton T, Hazra R, Townley E, Buchanan A, Palumbo P


Poster presentation, Hall 1,
12:30 – 14:30 (THPEB114)

PROMISE 1077BF


Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component

Flynn P, Taha T, Cababasay M, Butler K, Fowler MG, Mofenson L, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanshanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga B, Masenya M, Nyati M, Theron G, Mulenga H, Shapiro D, and the PROMISE Study Team

Poster presentation, Hall 1,
12:30 – 14:30 (THPEB115)

P1026s


Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy


Momper JD, Best B, Wang J, Stek A, Cressey TR, Burchett S, Kreitchmann R, Shapiro DE, Smith E, Chakhtoura N, Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol Team


Oral presentation, Hall 11a,
16:45 – 17:00 (THAB0302)

 

← Publications Home

 

 

 

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.